Adjuvant Mitomycin C with an Alternative Cycle Strategy after surgical Excision in Conjunctival Melanoma: A Case Report

Melanoma of conjunctiva is a rare but aggressive malignancy that has a high probability of recurrence. Topical Mitomycin C (MMC) is being used more commonly as an adjuvant. Our report presents a female patient with a temporal, bulbar conjunctival pigmented mass. Malignant melanoma was confirmed by excision with amniotic membrane transplantation and adjunctive cryotherapy. Although there was initial recovery, recurrence occurred within three months. Adjuvant MMC 0.04% was started in four intermittent cycles, and each cycle was four days with a weekly pause. The regimen was also tolerated, and only mild ocular irritation was present. Six months follow-up showed that the lesion was partially regressed with visual acuity remaining normal. The present case demonstrates that adjuvant MMC using another cycle regimen is a possible and effective alternative to recurrent conjunctival melanoma.